Barlogie B - Search Results

1

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.

Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Yang J, et al. Among authors: barlogie b. Cancer Cell. 2006 Oct;10(4):295-307. doi: 10.1016/j.ccr.2006.08.025. Cancer Cell. 2006. PMID: 17045207 Free article.

2

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Yaccoby S, et al. Among authors: barlogie b. Br J Haematol. 2002 Feb;116(2):278-90. doi: 10.1046/j.1365-2141.2002.03257.x. Br J Haematol. 2002. PMID: 11841428 Free article.

3

Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.

Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Wen YJ, et al. Among authors: barlogie b. Blood. 2002 May 1;99(9):3280-5. doi: 10.1182/blood.v99.9.3280. Blood. 2002. PMID: 11964294 Free article.

4

Optimizing dendritic cell-based immunotherapy in multiple myeloma.

Yi Q, Desikan R, Barlogie B, Munshi N. Yi Q, et al. Among authors: barlogie b. Br J Haematol. 2002 May;117(2):297-305. doi: 10.1046/j.1365-2141.2002.03411.x. Br J Haematol. 2002. PMID: 11972511 Free article.

5

Beta(2)-microglobulin as a negative growth regulator of myeloma cells.

Min R, Li Z, Epstein J, Barlogie B, Yi Q. Min R, et al. Among authors: barlogie b. Br J Haematol. 2002 Aug;118(2):495-505. doi: 10.1046/j.1365-2141.2002.03635.x. Br J Haematol. 2002. PMID: 12139738 Free article.

6

Antimyeloma efficacy of thalidomide in the SCID-hu model.

Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Yaccoby S, et al. Among authors: barlogie b. Blood. 2002 Dec 1;100(12):4162-8. doi: 10.1182/blood-2002-03-0939. Epub 2002 Aug 8. Blood. 2002. PMID: 12393672 Free article.

7

Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.

Xie J, Wang Y, Freeman ME 3rd, Barlogie B, Yi Q. Xie J, et al. Among authors: barlogie b. Blood. 2003 May 15;101(10):4005-12. doi: 10.1182/blood-2002-11-3368. Epub 2003 Jan 16. Blood. 2003. PMID: 12531797 Free article.

8

Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.

Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Morris CL, et al. Among authors: barlogie b. Br J Haematol. 2003 Feb;120(3):413-23. doi: 10.1046/j.1365-2141.2003.04107.x. Br J Haematol. 2003. PMID: 12580955 Free article.

9

Cancer and the microenvironment: myeloma-osteoclast interactions as a model.

Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Yaccoby S, et al. Among authors: barlogie b. Cancer Res. 2004 Mar 15;64(6):2016-23. doi: 10.1158/0008-5472.can-03-1131. Cancer Res. 2004. PMID: 15026338

10

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.

Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Zangari M, et al. Among authors: barlogie b. Br J Haematol. 2005 Oct;131(1):71-3. doi: 10.1111/j.1365-2141.2005.05733.x. Br J Haematol. 2005. PMID: 16173965 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

697 results

Search Page

Filters